SEC Comment Letter for Annovis Bio, Inc. (ANVS) (CIK 0001477845) (ANVS) — Jun 6, 2019
Annovis Bio, Inc. (ANVS) (CIK 0001477845)
Date: June 6, 2019 · CIK: 0001477845 · Accession: 0000000000-19-009522
AI Filing Summary & Sentiment
Reasoning
Letter
May 20, 2019 Maria Maccecchini, Ph.D. President and Chief Executive Officer Annovis Bio, Inc. 1055 Westlakes Drive, Suite 300 Berwyn, PA 19312 Re:Annovis Bio, Inc. Draft Registration Statement on Form S-1 Submitted May 15, 2019 CIK No. 0001477845 Dear Dr. Maccecchini: We have reviewed your draft registration statement and have the following comment. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing the information you provide in response to these comments and your amended draft registration statement or filed registration statement, we may have additional comments. Draft Registration Statement on Form S-1 submitted May 15, 2019 Index to Financial Statements, page F-1 1.We note the financial statements included in the draft registration statement are as of a date 135 days or more before the date the document was submitted. Based on your representation that at the time of the contemplated offering, you will be required to present the March 31, 2019 interim financial statements in the document, please update your disclosure to include these financial statements. We will not perform a detailed examination of the draft registration statement until you do so.
FirstName LastNameMaria Maccecchini, Ph.D. Comapany NameAnnovis Bio, Inc. May 20, 2019 Page 2 FirstName LastName Maria Maccecchini, Ph.D. Annovis Bio, Inc. May 20, 2019 Page 2 You may contact Jim Rosenberg at 202-551-3679 if you have questions regarding comments on the financial statements and related matters. Please contact Mary Beth Breslin at 202-551-3625 with any other questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: John W. Kauffman
Show Raw Text
May 20, 2019
Maria Maccecchini, Ph.D.
President and Chief Executive Officer
Annovis Bio, Inc.
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312
Re:Annovis Bio, Inc.
Draft Registration Statement on Form S-1
Submitted May 15, 2019
CIK No. 0001477845
Dear Dr. Maccecchini:
We have reviewed your draft registration statement and have the following comment. In
some of our comments, we may ask you to provide us with information so we may better
understand your disclosure.
Please respond to this letter by providing the requested information and either submitting
an amended draft registration statement or publicly filing your registration statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances or do not
believe an amendment is appropriate, please tell us why in your response.
After reviewing the information you provide in response to these comments and your
amended draft registration statement or filed registration statement, we may have additional
comments.
Draft Registration Statement on Form S-1 submitted May 15, 2019
Index to Financial Statements, page F-1
1.We note the financial statements included in the draft registration statement are as of a
date 135 days or more before the date the document was submitted. Based on your
representation that at the time of the contemplated offering, you will be required to present
the March 31, 2019 interim financial statements in the document, please update your
disclosure to include these financial statements. We will not perform a detailed
examination of the draft registration statement until you do so.
FirstName LastNameMaria Maccecchini, Ph.D.
Comapany NameAnnovis Bio, Inc.
May 20, 2019 Page 2
FirstName LastName
Maria Maccecchini, Ph.D.
Annovis Bio, Inc.
May 20, 2019
Page 2
You may contact Jim Rosenberg at 202-551-3679 if you have questions regarding
comments on the financial statements and related matters. Please contact Mary Beth Breslin at
202-551-3625 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: John W. Kauffman